ライフサイエンスコーパス: basal cell carcinoma

1 curative surgery or radiation or metastatic basal cell carcinoma.

2 um antibodies and cSCC or between betaPV and basal cell carcinoma.

3 therapies for Hh-dependent cancers, such as basal cell carcinoma.

4 clinical practice for patients with advanced basal cell carcinoma.

5 nalling inhibitor, in patients with advanced basal cell carcinoma.

6 CN1 and CCN2 may provide clinical benefit in basal cell carcinoma.

7 US Food and Drug Administration for advanced basal cell carcinoma.

8 nd progression of several cancers, including basal cell carcinoma.

9 smodegib for metastatic and locally advanced basal cell carcinoma.

10 elioma, meningioma, renal cell carcinoma and basal cell carcinoma.

11 at are novel and have not been documented in basal cell carcinoma.

12 in the US and is second in incidence only to basal cell carcinoma.

13 rms of cancer, including medulloblastoma and basal cell carcinoma.

14 seases such as genital warts, keratosis, and basal cell carcinoma.

15 n the proliferation of colorectal cancer and basal cell carcinoma.

16 t (1 malignancy) also developed a periocular basal cell carcinoma.

17 ncluding medulloblastoma, ameloblastoma, and basal cell carcinoma.

18 is approved for use in adults with advanced basal-cell carcinoma.

19 surgical excision in patients with low-risk basal-cell carcinoma.

20 py exists for locally advanced or metastatic basal-cell carcinoma.

21 % response rate among patients with advanced basal-cell carcinoma.

22 d greater than 10% for those with metastatic basal-cell carcinoma.

23 naling are implicated in the pathogenesis of basal-cell carcinoma.

24 patients with locally advanced or metastatic basal-cell carcinoma.

25 but are of unproven benefit, especially for basal-cell carcinoma.

26 H1) and smoothened homologue (SMO), occur in basal-cell carcinoma.

27 r activity in locally advanced or metastatic basal-cell carcinoma.

28 d cords, and ulceration were associated with basal cell carcinomas.

29 ltiple, recurrent, locally aggressive facial basal cell carcinomas.

30 TGF-beta signaling in several cell types in basal cell carcinomas.

31 tions in Ptch1 lead to the formation of skin basal cell carcinomas.

32 UVR in sunlight causes mutations that drive basal cell carcinomas.

33 rowth, with excessive signaling resulting in basal cell carcinomas.

34 nderlie the development of infundibulocystic basal cell carcinomas.

35 as well as renal, breast, lung, gastric, and basal cell carcinomas.

36 ve for select locally advanced or metastatic basal cell carcinomas.

37 onfirmed and at least six clinically evident basal-cell carcinomas.

38 s included reduction in the size of existing basal-cell carcinomas.

39 les taken from sites of clinically regressed basal-cell carcinomas.

40 responses in locally advanced and metastatic basal-cell carcinomas.

41 ib dosing regimens in patients with multiple basal-cell carcinomas.

42 the pivotal molecular abnormality underlying basal-cell carcinomas.

43 ent for squamous-cell carcinoma and for most basal-cell carcinomas.

44 long-term regimens in patients with multiple basal-cell carcinomas.

45 ehog signalling underlies the development of basal-cell carcinomas.

46 confirmed, including 9 melanomas (0.5%), 37 basal cell carcinomas (1.9%), and 1 squamous cell carcin

47 icial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4

48 types were represented in this analysis: 166 basal cell carcinomas, 146 squamous cell carcinomas, and

49 up and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39] lower rate

50 3%]), cutaneous SCC (11 of 21 tumors [52%]), basal cell carcinoma (3 of 4 tumors [75%]), and ACC (5 o

51 (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (1

52 o imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcin

53 diameter) of existing clinically significant basal-cell carcinomas (-65% vs. -11%, P=0.003).

54 n lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 hemangiomas, 4 der

55 luding 55 melanocytic nevi, 20 melanomas, 15 basal cell carcinomas, 7 solar lentigines or seborrheic

56 Tumors were overwhelmingly squamous and basal cell carcinomas (73% and 24%, respectively).

57 f cutaneous squamous cell carcinomas, 95% of basal cell carcinomas, 73% of conjunctival squamous cell

58 treatment option for patients with advanced basal cell carcinoma, a population that is difficult to

59 nown about patients' experiences of advanced basal cell carcinoma (aBCC) and basal cell carcinoma nev

60 now FDA-approved for patients with advanced basal cell carcinoma, acquired mutations in Smo can resu

61 currently in clinical trials for eradicating basal cell carcinoma, actinic keratosis, and squamous ce

62 on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment.

63 13), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metastatic basal cell c

64 n clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of pa

65 ns in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largel

66 ors are clinically effective in treatment of basal cell carcinoma and medulloblastoma, but fail thera

67 thway is best established in tumors, such as basal cell carcinoma and medulloblastoma, where the path

68 ivating mutations of the Hh pathway, such as basal cell carcinoma and medulloblastoma.

69 utive signaling has been well established in basal cell carcinoma and medulloblastoma.

70 Hh) pathway is known to drive development of basal cell carcinoma and medulloblastomas and to associa

71 re associated with an increased incidence of basal cell carcinoma and melanoma, and a nonstatisticall

72 included intradermal nevus misclassified as basal cell carcinoma and nonmelanocytic lesions (eg, seb

73 Hedgehog signaling, where Ptch1 loss causes basal cell carcinoma and Ptch1;Ptch2 loss disrupts skin

74 up period of at least 13 years, the IRRs for basal cell carcinoma and squamous cell carcinoma remaine

75 ere noted among the 42 with locally advanced basal cell carcinoma and two (15%, 2-45) among the 13 wi

76 Approximately 75% to 80% are basal cell carcinomas and 20% to 25% are squamous cell c

77 d specificity of 89-99% for the detection of basal cell carcinomas and can potentially serve as a rap

78 Dependence of basal cell carcinomas and medulloblastomas on the Hedgeh

79 ed as nonmelanocytic (primarily as pigmented basal cell carcinomas and squamous cell carcinomas).

80 than 20% for patients with locally advanced basal-cell carcinoma and greater than 10% for those with

81 Nonmelanoma skin cancers, such as basal-cell carcinoma and squamous-cell carcinoma, are co

82 xcluded patients with morphoeic or recurrent basal-cell carcinoma and those with Gorlin syndrome.

83 study, we enrolled patients with metastatic basal-cell carcinoma and those with locally advanced bas

84 y, had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adver

85 e number of new squamous-cell carcinomas and basal-cell carcinomas and the number of actinic keratose

86 treatment of actinic keratoses, superficial basal cell carcinoma, and genital warts.

87 n increased risk of squamous cell carcinoma, basal cell carcinoma, and melanoma.

88 increased risk for squamous cell carcinoma, basal cell carcinoma, and melanoma.

89 ngioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5%

90 d incidence rate ratios (IRRs) for melanoma, basal cell carcinoma, and squamous cell carcinoma by usi

91 ablished treatments for specific subtypes of basal-cell carcinoma, and the search for more effective

92 Although most basal-cell carcinomas are treated surgically, no effecti

93 evelopment and some forms of cancer, such as basal cell carcinoma, are transduced by the primary cili

94 es including actinic keratosis, squamous and basal cell carcinoma as well as verruca and psoriasis an

95 ared with surgery for superficial or nodular basal cell carcinoma at low-risk sites in our noninferio

96 lly confirmed primary nodular or superficial basal-cell carcinoma at low-risk sites.

97 ndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland

98 baseline in the number of clinically evident basal-cell carcinomas at week 73.

99 a genome-wide association study on cutaneous basal cell carcinoma (BCC) among 2045 cases and 6013 con

100 f the variability in NMSC incidence: 82% for basal cell carcinoma (BCC) and 85% for squamous cell car

101 Basaloid skin tumors, including basal cell carcinoma (BCC) and basaloid follicular hamar

102 s in human skin biopsy samples diagnosed for basal cell carcinoma (BCC) and compared with healthy ski

103 Patients with basal cell carcinoma (BCC) and cutaneous squamous cell c

104 his method to differentiate two skin tumors, basal cell carcinoma (BCC) and Merkel cell carcinoma (MC

105 ary outcomes were time to development of new basal cell carcinoma (BCC) and new invasive squamous cel

106 We report a case of local recurrence of basal cell carcinoma (BCC) and ocular complications foll

107 Whether susceptible people develop both basal cell carcinoma (BCC) and squamous cell carcinoma (

108 mance of this methodology on differentiating basal cell carcinoma (BCC) and squamous cell carcinoma (

109 f non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (

110 avirus (HPV) infection in the development of basal cell carcinoma (BCC) and squamous cell carcinoma (

111 Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

112 f nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (

113 tance: Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

114 ng DSCMs before and after training to detect basal cell carcinoma (BCC) and squamous cell carcinoma (

115 in cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas

116 Basal cell carcinoma (BCC) are common in this age group

117 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date.

118 nacone et al. investigate the role of HPV in basal cell carcinoma (BCC) by assessing the presence of

119 , 285 squamous cell carcinoma (SCC), and 300 basal cell carcinoma (BCC) cases, and 870 common control

120 The effect of UVR on human basal cell carcinoma (BCC) epidemiology is complex-the i

121 Although the number of new cases of basal cell carcinoma (BCC) has increased rapidly in the

122 elimination of superficial and early nodular basal cell carcinoma (BCC) in 2 cases using RCM imaging

123 r et al. (this issue) assess the risk of new basal cell carcinoma (BCC) in the Veterans Affairs topic

124 Basal cell carcinoma (BCC) incidence is increasing, part

125 Basal cell carcinoma (BCC) incidence is increasing, part

126 Basal cell carcinoma (BCC) is an excellent model system

127 Basal cell carcinoma (BCC) is characterized by frequent

128 Basal cell carcinoma (BCC) is the most common cancer in

129 Basal cell carcinoma (BCC) is the most common cancer wor

130 Basal cell carcinoma (BCC) is the most common malignancy

131 Basal cell carcinoma (BCC) is the most common skin cance

132 Basal cell carcinoma (BCC) is the most common type of sk

133 These associations were confined to basal cell carcinoma (BCC) of the skin (rs2228529, OR 1.

134 Basal cell carcinoma (BCC) of the skin is driven by this

135 Basal cell carcinoma (BCC) of the skin is the most commo

136 Consecutively diagnosed cases of basal cell carcinoma (BCC) of the skin were histological

137 ith samples taken before diagnosis of SCC or basal cell carcinoma (BCC) of the skin were identified.

138 Basal cell carcinoma (BCC) of the skin, the most common

139 lent or aggressive, as is the case with skin basal cell carcinoma (BCC) or cerebellar medulloblastoma

140 s between cigarette smoking and incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (S

141 Basal cell carcinoma (BCC) represents 90% of malignant e

142 rum 25-hydroxyvitamin D (25(OH)D) levels and basal cell carcinoma (BCC) risk in a nested case-control

143 the cancer-associated microRNA-21 (miR21) in basal cell carcinoma (BCC) skin tumors.

144 (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) tumorigenesis, and reduces BC

145 apillomavirus (HPV) DNA has been detected in basal cell carcinoma (BCC) tumors, but most epidemiologi

146 n size with squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) were evaluated for the factor

147 melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC)) in prospective studies simul

148 itor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinica

149 a new type of targeted therapy for advanced basal cell carcinoma (BCC), and their long-term effects,

150 ts who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integ

151 he INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased pr

152 cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a result of immun

153 risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KCs) o

154 ted in a variety of human cancers, including basal cell carcinoma (BCC), medulloblastoma (MB) and emb

155 ry outcomes were time to first appearance of basal cell carcinoma (BCC), squamous cell carcinoma (SCC

156 in various cell processes, is upregulated in basal cell carcinoma (BCC), supporting a possible tumori

157 Importance: Rates of skin cancer, including basal cell carcinoma (BCC), the most common cancer, have

158 g (Hh) signaling leads to the development of basal cell carcinoma (BCC), the most common human cancer

159 Basal cell carcinoma (BCC), the most common human cancer

160 tion exposure is the primary risk factor for basal cell carcinoma (BCC), the most common human malign

161 s directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cance

162 By contrast, the incidence of basal cell carcinoma (BCC), the other major keratinocyte

163 uence variants that confer risk of cutaneous basal cell carcinoma (BCC), we conduct a genome-wide ass

164 particularly evident in medulloblastoma and basal cell carcinoma (BCC), where inhibitors targeting t

165 This article provides an update on basal cell carcinoma (BCC), with a focus on the advanced

166 umption is associated with risk of cutaneous basal cell carcinoma (BCC).

167 verall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC).

168 treatment of locally advanced and metastatic basal cell carcinoma (BCC).

169 SC, mainly squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).

170 us cell carcinoma, and a superficial type of basal cell carcinoma (BCC).

171 moothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC).

172 up Study, we prospectively examined risks of basal cell carcinoma (BCC, 22,786 cases), squamous cell

173 way is aberrantly activated in a majority of basal cell carcinomas (BCC).

174 procaspase-8) in association with cutaneous basal-cell carcinoma (BCC) and linked to a germline SNP

175 There is a paucity of data on basal-cell carcinoma (BCC) in the United States, since m

176 Human basal cell carcinomas (BCCs) are associated with misacti

177 Basal cell carcinomas (BCCs) are diagnosed by clinical e

178 Advanced basal cell carcinomas (BCCs) frequently acquire resistan

179 Basal cell carcinomas (BCCs) in patients with Gorlin syn

180 The incidence of basal cell carcinomas (BCCs) is increasing globally, but

181 five groups have addressed this question for basal cell carcinomas (BCCs) of the skin.

182 Growth of basal cell carcinomas (BCCs) requires high levels of hed

183 Human basal cell carcinomas (BCCs) very frequently carry p53 m

184 However, their susceptibility to basal cell carcinomas (BCCs), a neoplasm considered orig

185 sting of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), are the most common human

186 hway in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia

187 have not, to our knowledge, been applied to basal cell carcinomas (BCCs).

188 in the skin and preventing the formation of basal cell carcinomas (BCCs).

189 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

190 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

191 e reveals that dermoscopy can help delineate basal cell carcinomas before surgical removal but that i

192 ns are causative of Gorlin syndrome (naevoid basal cell carcinoma), but detection rates > 70% have ra

193 duced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tum

194 c modality from which patients with advanced basal cell carcinoma can benefit substantially.

195 In some patients, all basal-cell carcinomas clinically regressed.

196 mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly as

197 d the development of new surgically eligible basal-cell carcinomas compared with placebo (0.4 [SD 0.2

198 on for small low-risk superficial or nodular basal-cell carcinoma dependent on factors such as patien

199 which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and

200 Basal-cell carcinoma developed in 1 patient receiving us

201 Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vi

202 Basal cell carcinomas displayed focal receptor positivit

203 We tested the anti-basal-cell carcinoma efficacy of vismodegib in a randomi

204 ons was reflected by the fact that all human basal cell carcinomas examined have detectable STAT3 pho

205 ma and an adenoma) and as controls on eyelid basal cell carcinomas, eyelid squamous cell carcinomas,

206 oved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate.

207 oma within the tumor bed of locally advanced basal cell carcinoma found during vismodegib treatment.

208 c/hypomelanotic malignant lesions (including basal cell carcinoma) gave a 93% sensitivity and 70% spe

209 ell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell

210 Medicaid subjects with basal cell carcinoma had a strong, negative QOL impact a

211 -71.0) of 453 patients with locally advanced basal cell carcinoma had an overall response (153 comple

212 %; 20.7-57.7) of 29 patients with metastatic basal cell carcinoma had an overall response (two comple

213 Patients with locally advanced basal cell carcinoma had to have been deemed ineligible

214 basal cell carcinoma and 31 with metastatic basal cell carcinoma) had received study drug and had th

215 Patients with advanced basal cell carcinoma have limited treatment options.

216 (HR = 1.15, 95% CI 1.11-1.19, p < 0.001, for basal cell carcinoma; HR = 1.21, 95% CI 1.17-1.25, p < 0

217 gery remains the best treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a u

218 rovide evidence that up-regulation of YAP in basal cell carcinoma impacts both aberrant keratinocyte

219 f melanoma; overall and by stage and risk of basal cell carcinoma in multivariable logistic regressio

220 ling strategy allowed objective diagnosis of basal cell carcinoma in skin tissue samples excised duri

221 Basal cell carcinoma in the very elderly were more commo

222 n, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mi

223 tance of repeated biopsy in locally advanced basal cell carcinomas in 2 clinical situations: (1) when

224 The number of basal cell carcinomas in the 5 years prior to enrollment

225 ypertelorism in three patients, and multiple basal cell carcinomas in the radiation field after age 1

226 Two basal cell carcinomas in the same patient and one case o

227 odalities to help delineate tumor margins of basal cell carcinomas in the setting of Mohs micrographi

228 ular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%).

229 oma in ten (12%), asthenia in four (5%), and basal-cell carcinoma in four (5%).

230 cinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell ne

231 Patients with multiple basal-cell carcinomas, including those with basal-cell n

232 al, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell n

233 Basal-cell carcinoma is the most common form of skin can

234 ecule and are indicated for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell c

235 The mean number of basal-cell carcinoma lesions at week 73 was reduced from

236 rm of Smo, and abrogate the proliferation of basal cell carcinoma-like cancer cells.

237 basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC).

238 mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical terat

239 eic keratosis, lichen planus-like keratosis, basal cell carcinomas) misclassified as melanocytic beca

240 of advanced basal cell carcinoma (aBCC) and basal cell carcinoma nevus syndrome (BCCNS), a rare gene

241 en's Hospital Oakland Research Institute and Basal Cell Carcinoma Nevus Syndrome Life Support Network

242 Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or

243 ose below 75 nmol l(-1) more often developed basal cell carcinoma (odds ratio (OR)=1.51 (95% confiden

244 disorder characterized by multiple cutaneous basal cell carcinomas, odontogenic keratocysts, skeletal

245 athway in cancer has been best documented in basal cell carcinoma of the skin.

246 oma, but it is yet unclear if it can prevent basal cell carcinoma or melanoma.

247 th histologically confirmed locally advanced basal cell carcinoma or metastatic basal cell carcinoma

248 ed a diagnosis of and were being treated for basal cell carcinoma or squamous cell carcinoma (cases)

249 as also associated with an increased risk of basal cell carcinoma (OR, 1.19 [95% CI, 1.14-1.25], 9% f

250 ing (mean 0.6 [0.72] new surgically eligible basal-cell carcinomas per patient per year vs 1.7 [1.8]

251 lacebo (0.4 [SD 0.2] new surgically eligible basal-cell carcinomas per patient per year vs 30.0 [7.8]

252 (n=15; two [SD 0.12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1.32]

253 er year vs 34 [1.32] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

254 er year vs 1.7 [1.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

255 r year vs 30.0 [7.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

256 umber of new nonmelanoma skin cancers (i.e., basal-cell carcinomas plus squamous-cell carcinomas) dur

257 The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with im

258 d in a clinical trial testing vismodegib for basal cell carcinoma prevention (NCT00957229), using pre

259 ignancies and the squamous cell carcinoma-to-basal cell carcinoma ratio increased with time postgraft

260 The squamous cell carcinoma to basal cell carcinoma ratio was 1:3.

261 erruption of treatment, which is followed by basal-cell carcinoma recurrence.

262 etween sun-exposure patterns and subtypes of basal-cell carcinoma remains undetermined.

263 lleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO)

264 e is that of a patient with locally advanced basal cell carcinoma responsive to vismodegib but with a

265 other hyperproliferative disorders, such as basal cell carcinoma, sAC staining was similar to normal

266 In patients with CLL and non-basal cell carcinoma skin cancer, mortality is as high f

267 Basal cell carcinoma, solar keratosis, and colorectal ca

268 on (aOR, 2.13; 95% CI, 1.31-3.47; P=.002) or basal-cell carcinoma specific criteria (aOR, 9.35; 95% C

269 immunosuppressed = 8.9 years), 135 (27%) had basal cell carcinoma, squamous cell carcinoma or Bowen's

270 or tanning facility and an increased risk of basal cell carcinoma, squamous cell carcinoma, and melan

271 We observed no overall increased risk for basal cell carcinoma, squamous cell carcinoma, or melano

272 d within 1 second each, including melanomas, basal cell carcinomas, squamous cell carcinomas, actinic

273 Unlike basal-cell carcinoma, squamous-cell carcinomas can arise

274 scopy revealed increased tissue stiffness in basal cell carcinoma stroma compared to normal dermis.

275 In basal cell carcinoma stroma, CCN2-regulated genes type I

276 Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genoder

277 Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal do

278 r sporadically or associated with the nevoid basal cell carcinoma syndrome.

279 dverse events over 24 months, which included basal-cell carcinoma (ten [3%] patients vs two [1%] pati

280 key RCM diagnostic criteria for melanoma and basal cell carcinoma that are reproducibly recognized am

281 with Gorlin syndrome with a locally advanced basal cell carcinoma that was stable while the patient w

282 point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical re

283 In 63 patients with locally advanced basal-cell carcinoma, the independently assessed respons

284 In 33 patients with metastatic basal-cell carcinoma, the independently assessed respons

285 organ transplant population at high risk for basal cell carcinoma, therapeutic options for locally ad

286 responses of metastatic or locally advanced basal-cell carcinoma to the drug.

287 d healing, systemic lupus erythematosus, and basal cell carcinoma tumor angiogenesis.

288 edly elevated in keratinocytes in human skin basal cell carcinoma tumor islands.

289 Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of n

290 the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basa

291 Vismodegib reduces basal-cell carcinoma tumour burden in patients with basa

292 No residual basal-cell carcinoma was detectable in 83% of biopsy sam

293 per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than wit

294 advanced basal cell carcinoma or metastatic basal cell carcinoma were recruited from regional referr

295 lanomas, 29 squamous cell carcinomas, and 38 basal cell carcinomas were diagnosed, with a higher prop

296 h showed negative results for both, and from basal cell carcinomas, which showed positive receptor re

297 Patients with histologically confirmed basal cell carcinoma who received at least one dose of s

298 ll carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for w

299 They report an increased risk of basal cell carcinoma with tetracycline use and of squamo

300 The risk of basal cell carcinoma within nevus sebaceus appears to be